ACTU (Actuate Therapeutics) Treasury Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Actuate Therapeutics's treasury stock for the quarter that ended in Dec. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Actuate Therapeutics Treasury Stock Historical Data

The historical data trend for Actuate Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Treasury Stock Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Treasury Stock

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Treasury Stock	Get a 7-Day Free Trial				-	-	-	-	-

Actuate Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.